Skip to content
Medical Health Aged Care

Research prompts calls to set higher tobacco retailer licence fees nationwide

Public Health Association of Australia / Australian and New Zealand Journal of Public Health 3 mins read

22nd September 2023 

 

New research into the impact of tobacco retailer licensing fees on tobacco availability has prompted public health experts to call on all Australian Governments to adopt a higher minimum standard of licensing regulation nationally to help drive down smoking rates. 

 

Tobacco licensing was changed significantly in South Australia in January 2007, when the annual cost of retail tobacco licences rose 15-fold from $12.90 to $200. A new study published in the Australian and New Zealand Journal of Public Health, builds on prior research that showed that the initial fee increase led to an almost 24 percent decrease in the number of tobacco retailers within two years.

 

Across Australia, there is a mishmash of licensing laws applied to retailers in order for them to legally be allowed to sell tobacco. This variation extends to the licence fee or price set, some jurisdictions not requiring a licence, with others running a notification rather than a licence scheme.

 

Co-author Professor Caroline Miller, Director of Health Policy at the South Australia Medical Health Research Institute (SAHMRI), says that the latest analysis of what happened in SA between 2009 and 2020 shows large fee increases are needed to prompt retailers to re-evaluate the sale of tobacco. 

 

“Since 2007, the fee in SA has only gradually been increased in line with indexation,” Prof Miller says.

 

“In the latest analysis, we found that the number of licences has continued to fall from 2,707 in 2009 to 1,810 in 2020, a 33 percent decline over 11 years. However, this is only an incremental change. 

 

“We also found that the remaining tobacco licences are even more concentrated in lower socio-economic areas. We need another fee increase here in SA to continue to reduce tobacco availability and support our community to quit, especially our most vulnerable.”

 

Adjunct Prof Terry Slevin, CEO, Public Health Association of Australia says that it’s ridiculous and bizarre that a product that has proven to be deadly is still so widely available in an enormous number of retail outlets.

 

“Tobacco is still the leading preventable cause of death and disability in Australia, yet continues to be sold in most supermarkets, corner stores, petrol stations, pubs and many other venues. No state or territory has any restriction on the number of outlets that can sell tobacco. 

 

“Tobacco smoking is estimated to cost Australia $137 billion, with those costs spanning health care and health system costs, loss of productivity, impact to families caring for someone with a tobacco caused illness, as well as ill health to individuals. Everyone else is left to pick up the cost and impact of tobacco, while retailers get off dirt cheap. 

 

“Tobacco licensing regulation in Australia is currently woeful and woefully inconsistent. In some states such as Victoria there is even no need for a licence to sell tobacco. In NSW you only need to let the government know once if you intend to sell cigarettes. In some states, the licence fee is ridiculously cheap.  

 

“This study reinforces the importance of introducing a higher standard of tobacco licensing across Australia, including high licence fees, to help reduce tobacco availability and support smokers who want to quit. 

 

“Improved licensing and higher fees would also prompt retailers to re-evaluate the economic value of being in the unethical business of selling tobacco. 

 

“The Government has committed to a target of decreasing smoking rates to below 10% by 2025, and to 5% or less by 2030.The National Tobacco Strategy has a number of actions relating to licensing, including considering restricting or prohibiting the sale of tobacco products in premises where alcohol is consumed, including vending machines; banning or restricting the sale of tobacco online and through smartphone applications; and considering a framework for a national licensing scheme. 

“To achieve lower smoking rates the Government is going to need a range of strong strategies in place. It’s time to put licensing on the radar and ask the question – do we really want tobacco this readily available?”

ENDS

For media interviews please contact: 

Hollie Harwood, Strategic Communications Advisor, Public Health Association of Australia, hharwood@phaa.net.au, 0400 762 010 

Paris Lord, Media and Communications Manager, Public Health Association of Australia, plord@phaa.net.au 0478 587 917

Note to editors: 

“Is it time to increase the cost of tobacco licences after 10 years of stagnation?” has been published online here

Please credit the Australian and New Zealand Journal of Public Health.

 

All articles are open access and can be found here: https://www.journals.elsevier.com/australian-and-new-zealand-journal-of-public-health

 

The Australian and New Zealand Journal of Public Health is a publication of the Public Health Association of Australia.

 

 

 

 

More from this category

  • Medical Health Aged Care, Research Development
  • 17/02/2025
  • 15:07
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg

The Australia New ZealandGynaecological Oncology Group (ANZGOG) is pleased to welcome internationally renowned Radiation Oncologist Professor Carien Creutzberg as a keynote speaker at the…

  • Contains:
  • Medical Health Aged Care
  • 17/02/2025
  • 11:51
Monash University

Monash Expert: Landmark approval of weight loss drug for heart disease

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The Therapeutic Goods Administration (TGA) has granted approval for semaglutide 2.4 mg (sold as Wegovy) to be used as a complementary therapy for reducing major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The approval follows findings from the SELECT trial, an international study involving more than 17,000 participants across 41 countries, including Australia. Results published in late 2023 showed that Wegovy reduced cardiovascular events by 20 percent in people…

  • Medical Health Aged Care
  • 17/02/2025
  • 10:11
Smith & Nephew UK Ltd

Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand

First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair*After anchor insertionSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE◊ Adjustable Achilles Reconstruction and ULTRABRACE◊ Adjustable Ankle Instability Techniques are changing the way foot & ankle surgeons perform these repairs by allowing them to refine and optimise suture tension after anchor insertion.The ability to adjust tension for specific patients allows the surgeon to give the precise amount of range-of-motion…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.